Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, has announced a license agreement with Germany’s Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology.
This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset.
Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network.
Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses.
K Pro’s reasoning capabilities support human-led analysis and self-driven campaigns for hypothesis generation, testing and prioritization.
This agreement between Owkin and Boehringer Ingelheim shows how cutting-edge AI has the potential to enable data-driven pharmaceutical research. We believe the next decade of drug development will be defined by access to deep multimodal patient data and to AI Scientists – like K Pro – capable of reasoning over that data.
Thomas Clozel, MD, Co-founder and CEO, Owkin.
